BR112017004134A2 - ?sondas para imageamento de proteína de huntingtina? - Google Patents

?sondas para imageamento de proteína de huntingtina?

Info

Publication number
BR112017004134A2
BR112017004134A2 BR112017004134A BR112017004134A BR112017004134A2 BR 112017004134 A2 BR112017004134 A2 BR 112017004134A2 BR 112017004134 A BR112017004134 A BR 112017004134A BR 112017004134 A BR112017004134 A BR 112017004134A BR 112017004134 A2 BR112017004134 A2 BR 112017004134A2
Authority
BR
Brazil
Prior art keywords
imaging probes
huntingtin protein
protein imaging
huntingtin
probes
Prior art date
Application number
BR112017004134A
Other languages
English (en)
Portuguese (pt)
Inventor
Dominguez Celia
John Brown Christopher
CLARK-FREW Daniel
Simon Walter Daryl
Alexander Weddell Derek
James WIGGINTON Ian
Morao Inaki
Wityak John
Bard Jonathan
George Taylor Malcolm
Edward Prime Michael
Richard Giles Paul
David Johnson Peter
René Gabriel GALAN Sébastien
Martin KRÜLLE Thomas
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of BR112017004134A2 publication Critical patent/BR112017004134A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/6823Release of bound markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/0412Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0419Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112017004134A 2014-08-29 2015-08-28 ?sondas para imageamento de proteína de huntingtina? BR112017004134A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043617P 2014-08-29 2014-08-29
PCT/US2015/047427 WO2016033460A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (1)

Publication Number Publication Date
BR112017004134A2 true BR112017004134A2 (pt) 2017-12-12

Family

ID=55400659

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004134A BR112017004134A2 (pt) 2014-08-29 2015-08-28 ?sondas para imageamento de proteína de huntingtina?

Country Status (14)

Country Link
US (1) US10907197B2 (enExample)
EP (1) EP3190888B1 (enExample)
JP (1) JP2017528520A (enExample)
KR (1) KR20170047341A (enExample)
CN (1) CN107105655A (enExample)
AU (2) AU2015308709B2 (enExample)
BR (1) BR112017004134A2 (enExample)
CA (1) CA2959505A1 (enExample)
EA (1) EA201790408A1 (enExample)
ES (1) ES2818107T3 (enExample)
IL (1) IL250804A0 (enExample)
MX (1) MX2017002705A (enExample)
SG (1) SG11201701580XA (enExample)
WO (1) WO2016033460A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3186233T3 (pl) 2014-08-29 2022-02-28 Chdi Foundation, Inc. Sondy do obrazowania białka huntingtyny
WO2016033440A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
ES2841746T3 (es) 2014-08-29 2021-07-09 Chdi Foundation Inc Sondas para la imagen de la proteína de Huntington
HRP20211156T1 (hr) 2015-08-28 2021-12-24 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
CN106632002A (zh) * 2016-09-28 2017-05-10 贵州大学 一种依托考昔及其对照品5‑氯‑3‑(4‑(甲基磺酰基)苯基)‑2,3‑联吡啶的制备工艺
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
CN108178764A (zh) * 2018-01-09 2018-06-19 天津科技大学 呋喃并[2,3-b]吡啶类化合物及无金属催化的合成方法
JP7619952B2 (ja) 2019-02-25 2025-01-22 シーエイチディーアイ ファウンデーション,インコーポレーテッド 変異型ハンチンチンタンパク質を標的とするための化合物及びその使用
JP2023536886A (ja) * 2020-08-06 2023-08-30 シーエイチディーアイ ファウンデーション,インコーポレーテッド ハンチンチンタンパク質をイメージングするためのヘテロビアリール化合物及びイメージング剤
BR112023020857A2 (pt) * 2021-04-08 2023-12-12 Chdi Foundation Inc Compostos de isoindolinona e agentes de imaginologia para imaginologia da proteína huntingtina

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1367836A (en) * 1918-04-29 1921-02-08 Int Precipitation Co Process for obtaining chlorids of potassium or other metals
US3985755A (en) * 1972-06-02 1976-10-12 E. R. Squibb & Sons, Inc. Pyridine containing isothiocyanobenzoxazoles
FR2524468B1 (fr) * 1982-04-06 1985-10-18 Sandoz Sa Nouveaux derives condenses du thiophene, leur preparation et leur utilisation comme azurants optiques
JPS60146877A (ja) * 1984-01-11 1985-08-02 Chisso Corp 2―置換―6―(5―置換―2―ピリミジニル)ナフタリン
JPH11171886A (ja) * 1997-12-08 1999-06-29 Mitsui Chem Inc アミジンまたはグアニジンを側鎖にもつピロリルベンズイミダゾール誘導体
IL162243A0 (en) * 2001-12-20 2005-11-20 Wyeth Corp Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
JP4875487B2 (ja) * 2003-03-14 2012-02-15 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション ベンゾチアゾール誘導体化合物、組成物および使用
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
JP2007504283A (ja) * 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
AU2003304416A1 (en) * 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
EP2752415B8 (en) 2006-08-24 2017-11-15 Australian Nuclear Science & Technology Organisation Fluorinated ligands for targeting peripheral benzodiazepine receptors
US7858803B2 (en) 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
KR101469275B1 (ko) 2007-06-01 2014-12-08 재단법인서울대학교산학협력재단 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물
US20090123373A1 (en) 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009146388A1 (en) * 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
EP2300481B1 (en) * 2008-05-30 2015-09-30 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
AU2009309027A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CN102388055B (zh) * 2009-04-02 2015-07-29 卡洛斯三世国家癌症研究中心基金会 咪唑并[2,1-b][1,3,4]噻二唑衍生物
GB0905664D0 (en) 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US20120263646A1 (en) * 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する2−アリールベンゾオキサゾール化合物
PL3186233T3 (pl) 2014-08-29 2022-02-28 Chdi Foundation, Inc. Sondy do obrazowania białka huntingtyny
WO2016033440A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
ES2841746T3 (es) 2014-08-29 2021-07-09 Chdi Foundation Inc Sondas para la imagen de la proteína de Huntington
HRP20211156T1 (hr) 2015-08-28 2021-12-24 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina

Also Published As

Publication number Publication date
KR20170047341A (ko) 2017-05-04
US20170292150A1 (en) 2017-10-12
AU2015308709B2 (en) 2020-01-02
EP3190888B1 (en) 2020-06-10
US10907197B2 (en) 2021-02-02
JP2017528520A (ja) 2017-09-28
SG11201701580XA (en) 2017-03-30
ES2818107T3 (es) 2021-04-09
AU2015308709A1 (en) 2017-03-23
WO2016033460A1 (en) 2016-03-03
EP3190888A4 (en) 2018-05-09
EA201790408A1 (ru) 2017-09-29
AU2020202226A1 (en) 2020-04-16
CA2959505A1 (en) 2016-03-03
CN107105655A (zh) 2017-08-29
EP3190888A1 (en) 2017-07-19
IL250804A0 (en) 2017-04-30
MX2017002705A (es) 2017-12-20

Similar Documents

Publication Publication Date Title
BR112017004141A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112017004134A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
BR112017004140A2 (pt) sondas para imageamento de proteína de huntingtina
IL270514B (en) Agricultural compositions
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
BR112017018872A2 (pt) combinação de um antagonista pd-1 e eribulina para tratamento de câncer
CR20170315A (es) Inhibridores bace 1 selectivos
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
BR112018005299A2 (pt) 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso
BR112017015455A2 (pt) agentes de imagiologia pet
BR112017008811A2 (pt) métodos para o tratamento de distúrbios renais
IT201700111990A1 (it) Scambiatore per uso medicale
RU2014115406A (ru) Применение 8-(трифторметил)бензо[f][1,2,3,4,5]пентатиепин-6-амина в качестве антидепрессанта
BR112017004947A2 (pt) composto ou sal farmaceuticamente aceitável, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento de mieloma múltiplo.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/42

Ipc: A61K 51/04 (2006.01), C07D 253/08 (2006.01), C07D

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]